Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease

NCT06721962 is registered in ClinicalTrials.gov with Tr1X, Inc. as lead sponsor.

NCT NCT06721962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06721962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease
Lead sponsor
Tr1X, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 5, 2025
Completion date
January 30, 2027
Enrollment
39 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

crohns disease